UK Legislators Get Involved In NICE’s Methods Review
Executive SummaryA UK parliamentary panel examining a wide range of issues affecting the availability of new treatments on the National Health Service is collecting evidence on possible topics that might be covered under the upcoming review of the appraisal methods used by health technology assessment body NICE. NICE itself is not publicly consulting on the scope of the review.
You may also be interested in...
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.